Research square · 2023
Vaccination with intravenous BCG protects macaques with pre-existing SIV infection from tuberculosis.
ПрепринтСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Larson Erica C, Ellis-Connell Amy L, Rodgers Mark A, Gubernat Abigail K, Gleim Janelle L, Moriarty Ryan V, Balgeman Alexis J, Ameel Cassaundra L, Jauro Solomon, Tomko Jaime A, Kracinovsky Kara B, Maiello Pauline, Borish H Jake, White Alexander G, Klein Edwin, Bucsan Allison N, Darrah Patricia A, Seder Robert A, Roederer Mario, Lin Philana Ling, Flynn JoAnne L, O'Connor Shelby L, Scanga Charles A
Аннотация
Tuberculosis (TB) is the most common cause of death in people living with HIV. BCG delivered intradermally (ID) is the only licensed vaccine to prevent TB. However, it offers little protection from pulmonary TB in adults. Intravenous (IV) BCG, but not ID BCG, confers striking protection against Mycobacterium tuberculosis (Mtb) infection and disease in rhesus macaques. We investigated whether IV BCG could protect against TB in macaques with a pre-existing SIV infection. There was a robust influx of airway T cells following IV BCG in both SIV-infected and SIV-naïve animals, with elevated antibody titers in plasma and airways. Following Mtb challenge, all 7 SIV-naïve and 9 out of 12 SIV-infected vaccinated animals were completely protected, without any culturable bacilli in their tissues. PBMC responses post-challenge indicated early clearance of Mtb in vaccinated animals regardless of SIV infection. These data support that IV BCG is immunogenic and efficacious in SIV-infected animals.